HOUSTON, March 9, 2021 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary aesthetic platform technology,
today announced that the company initiated a second pre-clinical
study in animals for potential treatment of liver fibrosis
intending to validate the first animal study that demonstrated
positive results for the potential treatment of liver fibrosis.
![Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company’s first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to accelerate the removal of unwanted tattoos (RAP device). In addition, higher energy versions of acoustic pulse devices are in early stages of development for potential stand-alone treatment of cellulite and other indications. (PRNewsfoto/Soliton, Inc.) Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company’s first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to accelerate the removal of unwanted tattoos (RAP device). In addition, higher energy versions of acoustic pulse devices are in early stages of development for potential stand-alone treatment of cellulite and other indications. (PRNewsfoto/Soliton, Inc.)](https://mma.prnewswire.com/media/871205/Soliton_Logo.jpg)
This additional pre-clinical study will seek to confirm the
positive findings of Soliton's initial pre-clinical study in
animals. The methods and conditions of the first study will remain
the same in this second study. In the initial study, validated
laboratory and histological assessments in a mouse model
demonstrated that Rapid Acoustic Pulse (RAP) therapy reduced the
effects of induced liver fibrosis 7-days following completion of
carbon tetrachloride (CCL4) induction by 42%. Post
treatment histology slides stained with picrosirius red (PSR)
showed a lower percentage of fibrosis from a single 2-minute RAP
treatment than the Control group.
"We look forward to conducting further studies seeking to
validate and build on the initial pre-clinical results our RAP
device demonstrated in treating liver fibrosis. We believe our RAP
device has the potential to become the first non-drug based
treatment option that can treat liver fibrosis and, in turn, aid
the estimated 6-7% of the world's population suffering from liver
fibrosis," said Dr. Chris Capelli,
Vice Chairman, CSO and Founder of Soliton. "Our RAP technology has
a strong scientific background, and we are excited to continue to
explore its potential in adjacent medical and aesthetic
applications."
The RAP device is currently cleared by the FDA for short-term
improvement in the appearance of cellulite. The RAP device is also
indicated for use as an accessory to the 1064 nm Q-Switched laser
for black ink tattoo removal in Fitzpatrick Skin Type I-III
patients. The device is not yet cleared for the treatment of liver
fibrosis.
Join our more than 200K
subscribers here to follow the
Company: https://soly-investors.com
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from The University of Texas on behalf of MD Anderson Cancer
Center. The Company's first FDA cleared commercial product,
RESONIC™, will use rapid pulses of acoustic shockwaves as an
accessory to lasers for the removal of unwanted tattoos and the
treatment of cellulite. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse (RAP) device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods. The
Company also believe the technology will provide the first
non-invasive acoustic technology to target the underlying causes of
dimples and ridges in cellulite. Soliton is investigating potential
additional capabilities of the RAP technology. The device is
currently cleared in the United
States only for use in tattoo removal and cellulite.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, which statements involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, our ability to successfully
replicate the results of this animal study in further clinical
studies in either animals or humans. These statements relate
to future events, future expectations, plans and prospects.
Although Soliton believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
actual results or outcomes may prove to be materially different
from the expectations expressed or implied by such forward-looking
statements. Soliton has attempted to identify forward-looking
statements by terminology including ''believes,'' ''estimates,''
''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,''
''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' "would,"
''should,'' ''approximately'' or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are only predictions
and involve known and unknown risks, uncertainties, and other
factors, including those discussed in our filings with the
Securities and Exchange Commission ("SEC"), including under the
heading " Risk Factors" in our most recently filed Form 10-K filed
with the SEC and as updated in our Form 10-Q filings and in our
other filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-announces-initiation-of-second-animal-study-for-potential-rap-treatment-of-liver-fibrosis-301242889.html
SOURCE Soliton, Inc.